Familial Chylomicronemia Syndrome Therapy
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, site-of-care, and prior authorization requirements for use of olezarsen (Tryngolza) and plozasiran (Redemplo) as adjuncts to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for Blue Cross NC members.
Added olezarsen (Tryngolza) to policy for the treatment of adults with familial chylomicronemia syndrome, as an adjunct to diet to reduce triglycerides.
For Tryngolza, added requirement for trial and failure of Redemplo (or intolerance/contraindication) and requirement for use of self-administered formulation unless criteria for supervised administration are met.
Added associated dosing, maximum units, and HCPCS codes C9399, J3490, and J3590 to the FDA label reference table for Tryngolza and Redemplo.
Removed requirement for medical record documentation for specialist requirement, concomitant use statement, and verification that secondary causes have been ruled out.
Changed policy name from 'Plozasiran (Redemplo ® )' to 'Familial Chylomicronemia Syndrome Therapy'.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.